Low density multiparticulate system for pulsatile release of meloxicam

被引:81
作者
Sharma, S [1 ]
Pawar, A [1 ]
机构
[1] Bharati Vidyapeeth Deemed Univ, Poona Coll Pharm & Res Ctr, Dept Pharmaceut, Maharashtra 411038, India
关键词
floating-pulsatile drug delivery system; porous calcium silicate; meloxicam; rheumatoid arthritis;
D O I
10.1016/j.ijpharm.2006.02.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A blend of floating and pulsatile principles of drug delivery system would have the advantage that a drug can be released in the upper G1 tract after a definite time period of no drug release. A multi particulate floating-pulsatile drug delivery system was developed using porous calcium silicate (Florite RE (R)) and sodium alginate, for time and site specific drug release of meloxicam. Meloxicam was adsorbed on the Florite RE (R) (FLR) by fast evaporation of solvent from drug solution containing dispersed FLR. Drug adsorbed FLR powder was used to prepare calcium alginate beads by ionotropic gelation method, using 3(2) factorial design. Developed formulations were evaluated for yield, entrapment efficiency, image analysis, surface topography, mechanical strength, apparent density, buoyancy studies and dissolution studies. Entrapment efficiency of different formulations varied from 70% to 94%. Formulations show a lag period ranging from 1.9 to 7.8 h in acidic medium followed by rapid release of meloxicam in simulated intestinal fluid USP, without enzymes (SIF). Complete drug release in SIF occurred in less than I h from the formulations. The size of beads varied from 2.0 to 2.7 mm for different batches. Prepared beads were spherical with crushing strength ranging from 182 to 1073 g. Floating time was controlled by density of beads and hydrophobic character of drug. A pulsatile release of meloxicam was demonstrated by a simple drug delivery system which could be useful in chronopharmacotherapy of rheumatoid arthritis. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:150 / 158
页数:9
相关论文
共 41 条
[1]   Evaluation of oral mucoadhesive microspheres in man on the basis of the pharmacokinetics of furosemide and riboflavin, compounds with limited gastrointestinal absorption sites [J].
Akiyama, Y ;
Nagahara, N ;
Nara, E ;
Kitano, M ;
Iwasa, S ;
Yamamoto, I ;
Azuma, J ;
Ogawa, Y .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1998, 50 (02) :159-166
[2]   Colonic metabolism of ranitidine: implications for its delivery and absorption [J].
Basit, AW ;
Lacey, LF .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 227 (1-2) :157-165
[3]  
Bolton S., 1997, PHARM STAT PRACTICAL
[4]   Use of commercial porous ceramic particles for sustained drug delivery [J].
Byrne, RS ;
Deasy, PB .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 246 (1-2) :61-73
[5]   Aldosterone release during the sleep-wake cycle in humans [J].
Charloux, A ;
Gronfier, C ;
Lonsdorfer-Wolf, E ;
Piquard, F ;
Brandenberger, G .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1999, 276 (01) :E43-E49
[6]   Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: Failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis [J].
Crofford, LJ ;
Kalogeras, KT ;
Mastorakos, G ;
Magiakou, MA ;
Wells, J ;
Kanik, KS ;
Gold, PW ;
Chrousos, GP ;
Wilder, RL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (04) :1279-1283
[7]   Circadian rhythms in RA [J].
Cutolo, M ;
Seriolo, B ;
Craviotto, C ;
Pizzorni, C ;
Sulli, A .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (07) :593-596
[8]   Formulation strategies for absorption windows [J].
Davis, SS .
DRUG DISCOVERY TODAY, 2005, 10 (04) :249-257
[9]   NITRATE TOLERANCE - A REVIEW OF THE EVIDENCE [J].
FLAHERTY, JT .
DRUGS, 1989, 37 (04) :523-550
[10]  
GAZZANIGA A, 1995, P INT S CONTR REL BI, V22, P242